NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, today announced that the first...
HONG KONG, May 29, 2026 /PRNewswire/ -- Against the backdrop of China's continued emphasis on the real economy under the "15th Five-Year Plan" and the...
JINCHANG, China, May 29, 2026 /PRNewswire/ -- In May 2026, Zhang Wei, person in charge of Jinchuan District Public Training Base Project in Jinchang City,...